Hikma Pharmaceuticals And 2 British Biotech Stocks To Watch

Global financial authorities have just agreed on new rules to improve transparency and reduce risks in the banking system, and that can push investors to look harder for growth away from traditional lenders. UK biotech shares sit right in that conversation. You get companies trying to solve hard medical problems, backed by balance sheets that are not stretched. This piece highlights three of the better quality biotech stocks screened on those foundations.

The three UK biotech stocks below are a sample from a wider search, and the full screen surfaced 3 more companies with equally grounded balance sheets and compelling stories that are not included here. To identify and analyze higher conviction biotech opportunities, head straight to the Biotech Stocks screener.

Hikma Pharmaceuticals (LSE:HIK)

Hikma Pharmaceuticals sits at the crossover between biotech-style oncology injectables and broader generic medicine, which is exactly what this screener looks for. The appeal is that oncology products plug into a wider engine of injectables, branded drugs, and retail generics.

Hikma Pharmaceuticals develops and sells generic, specialty, and branded medicines across injectables, oral, and respiratory formats, with Injectables contributing about US$1.4b of revenue, Hikma Rx US$1.0b, Branded US$914 million, and Other US$46 million. The group is valued at roughly £3.4b by the market.

Continued emphasis on high-value, complex generics and specialty injectables, supported by both internal R&D and strategic acquisitions (such as Xellia), directly aligns with the increasing adoption of generics by healthcare systems seeking cost containment, providing Hikma with higher-margin growth opportunities and potential earnings expansion.

What really matters now is how one quiet shift in Hikma Pharmaceuticals’ mix could tilt both margins and growth expectations in either direction.

That shift is exactly where the full narrative for Hikma Pharmaceuticals explains how Hikma Pharmaceuticals’ mix, capital allocation, and risk profile could be quietly decoupling from headline generic peers.

Oxford Biomedica (LSE:OXB)

Oxford Biomedica is a pure-play gene and cell therapy contractor, using its LentiVector platform and viral vector services to support pharma partners while generating most of its income from manufacturing services of about £88 million and development work of about £60 million, within a £632 million market value.

For the Biotech Stocks theme, Oxford Biomedica matters because it gives you direct exposure to viral vector gene therapy manufacturing through a CDMO model where partners carry the clinical risk and the business focuses on turning capacity and know how into revenue.

Expansion into AAV and other vector types diversify their revenue streams, reducing dependency on any single vector type and potentially enhancing overall earnings and EBITDA margins.

The real swing factor is how quickly contracted work actually converts into paid manufacturing runs, because that timing will shape both margins and confidence in future demand.

That timing question is exactly where the full narrative for Oxford Biomedica shows whether Oxford Biomedica is quietly building an accelerating CDMO engine or just treading water.

Genus (LSE:GNS)

Genus leans into the Biotech Stocks screener through its use of genetics and biotech tools in animal breeding, with Genus PIC generating about £355.8 million and Genus ABS about £299.8 million of revenue, and the group valued at roughly £1.4b.

Genus gives you exposure to biotech through the less crowded lens of animal genetics, where genomic tools shape herds that suppliers rely on for years.

Rapid shifts towards plant-based diets and alternative proteins present a structural threat to Genus's long-term addressable market, creating the risk that demand for animal genetics will stagnate or decline, placing persistent pressure on revenue growth.

What happens to Genus’s appeal hinges on how one pressure on future pricing and volumes resolves over the next few years.

How that pressure ultimately plays out is exactly what the full narrative for Genus unpacks, separating short term noise from the areas where Genus’s pricing power and volume story could be accelerating.

Seeking Alternatives Beyond Biotech Today

Fresh opportunities rarely stay quiet for long. Stocks building early momentum can sometimes be identified before prices move significantly if you act before the wider market takes notice.

• Explore potential sources of income by scanning a curated group of high-yield payers in the 1 dividend fortresses before yields change and investor interest broadens.
• Review early movers in artificial intelligence by running through the 37 profitable AI stocks that aren't just burning cash while these cash-generating specialists may still be less widely followed.
• Monitor the power upgrade cycle by tracking companies in the 39 power grid technology and infrastructure stocks while grid technology spending continues to attract attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com